A 2026 case report from a Tokyo clinic described reduced tic symptoms in three men with ADHD after they began low-dose extended-release guanfacine. The men started at 1 mg per day and were not taking other ADHD or tic medication.
The report is an early observation, not evidence that guanfacine reliably treats tics in adults. It included only three patients, had no comparison group or blinding, and followed them for about six weeks.
What happened in the three cases
The men had mild to moderate tics at the start. Combined motor and vocal tic scores fell from 20 to 5 in the first case, from 10 to 3 in the second, and from 19 to 15 in the third.
- Case 1: A 40-year-old man with Tourette syndrome reported that his vocal tics stopped within two to three days. His vocal tic score fell from 11 to 0, while his motor score fell from 9 to 5.
- Case 2: A 22-year-old man with chronic motor tics saw his motor tic score fall from 10 to 3 during the first week. He had no vocal tics.
- Case 3: A 27-year-old man with motor and vocal tics said after two weeks that his tics had roughly halved. His motor score fell from 9 to 7 and his vocal score from 10 to 8.
Two of the men reported fewer tics within days to a week, before they noticed changes in ADHD symptoms. Tic-control gains continued after doses were increased to 2 or 3 mg per day.
ADHD symptoms improved at higher doses
All three men initially scored above 65 on every Conners’ Adult ADHD Rating Scales subscale, indicating clinically elevated ratings within the report’s assessment framework.
After dose increases, some ADHD ratings improved. Case 1’s hyperactivity and restlessness score fell from 90 to 81, while inattention remained at 82. Case 2’s impulsivity and emotional-ups-and-downs score fell from 79 to 62. Case 3’s inattention and memory score fell from 88 to 78, and impulsivity fell from 88 to 81.
Most ADHD ratings remained in the clinically elevated range. Because tic changes appeared at 1 mg while some ADHD changes occurred at 2 or 3 mg, the researchers said the timing was consistent with a possible direct effect on tics rather than improvement caused first by better ADHD control. That interpretation remains untested in this case series.
How the findings fit earlier research
Previous research has produced mixed results. In a 2001 randomized trial involving 34 children with ADHD and tics, ADHD rating scores improved by 37% with guanfacine compared with 8% with placebo. Tic severity fell by 31% with guanfacine and 0% with placebo.
However, a 2017 randomized pilot trial of 34 children with chronic tics found similar tic-score reductions with extended-release guanfacine and placebo. The proportion rated much improved was 19% with guanfacine and 22% with placebo.
A 2020 randomized Japanese trial of 201 adults with ADHD found that extended-release guanfacine at 4 to 6 mg per day reduced ADHD scores by 11.6 points, compared with 7.3 points with placebo. Tics were not studied in that trial. Side effects were reported by 81.2% of participants receiving guanfacine and 62.0% receiving placebo; 19.8% and 3.0%, respectively, stopped because of side effects.
The three men in the case report received 1 to 3 mg per day, below the dose range used in the 2020 adult ADHD trial. None reported sedation or other side effects during the few weeks covered by the report, but this small, short observation cannot establish the medication’s broader safety profile.
Why the evidence remains preliminary
Tics naturally wax and wane, and the report notes that regression to the mean could explain some of the improvement. Without a placebo-treated comparison group, the study cannot determine how much change would have occurred without treatment.
The findings also came from one clinic and included only male participants with mild to moderate tics. A case report cannot establish that guanfacine caused the improvement or predict how often it would help other adults.
American Academy of Neurology guidelines give alpha-2 agonists such as guanfacine and clonidine a Level B recommendation when tics occur with ADHD. The same guidelines recommend Comprehensive Behavioral Intervention for Tics as an initial treatment where available. The new report raises a question for controlled adult trials; it does not resolve it.
AI tools were used to assist with the preparation of this article under our editorial standards.
Leave a Reply